Generex Biotechnology Corp. (GNBT)
-OTC Markets 0.04 
0.00(1.69%) 3:57PM EDT
| Prev Close: | 0.04 |
|---|
| Open: | 0.04 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | 2.14 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.04 - 0.04 |
|---|
| 52wk Range: | 0.02 - 0.10 |
|---|
| Volume: | 676,090 |
|---|
| Avg Vol (3m): | 2,848,900 |
|---|
| Market Cap: | 18.03M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.02 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to Articles of Inc.EDGAR Online(Mon, Jun 17)
- Generex Announces $1,225,000 Capital InvestmentPR Newswire(Mon, Jun 17)
- GENEREX BIOTECHNOLOGY CORP FinancialsEDGAR Online Financials(Fri, Jun 14)
- ASCO Interview of MD Anderson's Mittendorf on AE37 Breast Cancer Vaccine Now Available on Generex WebsitesPR Newswire(Thu, Jun 13)
- Generex Announces Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal Investigator on Company's AE37 Phase IIb Breast Cancer Efficacy TrialPR Newswire(Wed, Jun 12)
- GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExEDGAR Online(Mon, Jun 10)
- Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer PatientsPR Newswire(Wed, Jun 5)
- Positive Generex Data Underscores Cancer Immunotherapy Forecast Issued by CitiPR Newswire(Fri, May 31)
- Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer VaccinePR Newswire(Wed, May 22)
- Generex Comments on Results of Stockholders` MeetingPR Newswire(Wed, Apr 3)
- GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Mon, Apr 1)
- GENEREX BIOTECHNOLOGY CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, Mar 11)
- Generex Touts Pipeline Potential of Antigen Express SubsidiaryPR Newswire(Thu, Feb 7)
- Generex Biotechnology Corporation's CEO Discusses Investor Conference Call Transcriptat Seeking Alpha(Thu, Jan 31)
- GENEREX BIOTECHNOLOGY CORP Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, Jan 31)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2,627.23 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jul-11)
: | N/A |
|---|
| Quarterly EPS Est
(Oct-10)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
View More